Background: Salivary duct carcinoma (SDC) is one of the most aggressive malignant salivary gland tumors resembling high-grade mammary ductal carcinoma, with frequent local recurrence and regional lymph node and distant metastasis. SDC is often the absence of estrogen receptor and progesterone receptor, and Her2/neu overexpression. Treatment with molecular targeted therapy correlated well with long-term survival and therapeutic response in SDC patients. Purpose: We presented the clinicopathologic entity and treatment response of the two cases in Vietnam, firstly and compared it with the related literature to raise awareness of this tumor. Methods: The clinicopathological characteristics of two SDCs were recorded. Immunohistochemical staining was performed on ER, PR, HER2, and some markers. All SDC patients’ treatment responses and survival were accessed. Results and Conclusion: Two men with salivary carcinoma were classified into the breast enriched HER2 molecular subtype-like salivary duct carcinoma in an advanced stage, who have got the molecular targeted therapy as anti-HER2 combined with chemotherapy. They displayed a good response to novel targeted therapy.
Cite this paper
Do, K. H. , Do, T. A. , Le, D. T. , Nguyen, T. V. and Nguyen, C. V. (2022). The Breast Enriched HER2 Molecular Subtype-Like Salivary Duct Carcinoma: A Good Response to Novel Targeted Therapy in Two Advanced Disease Cases. Open Access Library Journal, 9, e9089. doi: http://dx.doi.org/10.4236/oalib.1109089.
Nagao, T., Licitra, L., Loening, T. and Williams, M. (2017) Salivary Duct Carcinoma. In: El-Naggar, A.K., Chan, J.K.C., Grandis, J.R., Takata, T. and Slootweg, P.J., Eds., WHO Classification of Head and Neck Tumours, 4th Edition, IARC Press, Lyon, 173-174.
Jaehne, M., Roeser, K., Jaekel, T., Schepers, J.D., Albert, N. and Loning, T. (2005) Clinical and Immunohistologic Typing of Salivary Duct Carcinoma: A Report of 50 Cases. Cancer, 103, 2526-2533. https://doi.org/10.1002/cncr.21116
Glisson, B., Colevas, A.D., Haddad, R., Krane, J., El-Naggar, A., Kies, M., et al. (2004) HER2 Expression in Salivary Gland Carcinomas: Dependence on Histological Subtype. Clinical Cancer Research, 10, 944-946.
https://doi.org/10.1158/1078-0432.CCR-03-0253
Cornolti, G., Ungari, M., Morassi, M.L., Facchetti, F., Rossi, E., Lombardi, D., et al. (2007) Amplification and Overexpression of HER2/neu Gene and HER2/neu Protein in Salivary Duct Carcinoma of the Parotid Gland. Archives of Otolaryngology—Head & Neck Surgery, 133, 1031-1036.
https://doi.org/10.1001/archotol.133.10.1031
Williams, M.D., Roberts, D.B., Kies, M.S., Mao, L., Weber, R.S. and El-Naggar, A.K. (2010) Genetic and Expression Analysis of HER-2 and EGFR Genes in Salivary Duct Carcinoma: Empirical and Therapeutic Significance. Clinical Cancer Research, 16, 2266-2274. https://doi.org/10.1158/1078-0432.CCR-09-0238
AL-Qahtani, K.H., Tunio, M.A., Bayoumi, Y., Gurusamy, V.M., Bahamdain, F.A.A. and Fatani, H. (2016) Clinicopathological Features and Treatment Outcomes of the Rare, Salivary Duct Carcinoma of Parotid Gland. Journal of Otolaryngology—Head and Neck Surgery, 45, Article No. 32. https://doi.org/10.1186/s40463-016-0146-2
Limaye, S.A., Posner, M.R., Krane, J.F., Fonfria, M., Lorch, J.H., Dillon, D.A., et al. (2013) Trastuzumab for the Treatment of Salivary Duct Carcinoma. The Oncologist, 18, 294-300. https://doi.org/10.1634/theoncologist.2012-0369
Foschini, M.P. (2019) Rare and Salivary Gland-Type Tumors: Introduction. In: Lokuhetty, D., White, V. A., Watanabe, R. and Cree, I. A., Eds., Breast Tumours, WHO Classification of Tumours, 5th Edition, IARC Press, Lyon, 139.
Nguyen, C.V., Nguyen, Q.T., Vu, H.T.N., Pham, K.H. and Phung, H.T. (2021) Molecular Classification Predicts Survival for Breast Cancer Patients in Vietnam: A Single Institutional Retrospective Analysis. International Journal of Clinical and Experimental Pathology, 14, 322-337.
Nakaguro, M., Sato, Y., Tada, Y., Kawakita, D., Hirai, H., Urano, M., et al. (2020) Prognostic Implication of Histopathologic Indicators in Salivary Duct Carcinoma: Proposal of a Novel Histologic Risk Stratification Model. The American Journal of Surgical Pathology, 44, 526-535. https://doi.org/10.1097/PAS.0000000000001413
Takahashi, H., Tada, Y., Saotome, T., Akazawa, K., Ojiri, H., Fushimi, C., et al. (2019) Phase II Trial of Trastuzumab and Docetaxel in Patients with Human Epidermalgrowt Factor Receptor 2-Positive Salivary Duct Carcinoma. Journal of Clinical Oncology, 37, 125-134. https://doi.org/10.1200/JCO.18.00545
